The Company is developing drug conjugate therapies with improved therapeutic index over contemporary ADCs. They have innovated a platform based on Tunable Drug Conjugate (TDCs) therapies used to directly target the delivery of toxins to tumors. The lead therapeutic program targets Folate Receptor alpha and has been validated in the clinic by ADCs, providing a de-risked benchmark for platform validation and candidate development. Additionally, their patented SiLinker system provides a tunable range of cleavage rates for a faster approach, with better tumor penetration.
Alexandria Innovation Center
555 Heritage Drive, Suite 165
Jupiter, FL 33458
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.